Latest from Moffitt

There was a high concordance between central tissue and plasma circulating tumor DNA testing for EGFR mutations in patients enrolled in the phase III FLAURA study of frontline osimertinib (Tagrisso) in NSCLC.
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the potential with the combination of ibrutinib (Imbruvica) and ublituximab (TGR-1101) in patients with chronic lymphocytic leukemia (CLL).
Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the potential with venetoclax (Venclexta) in patients with mantle cell lymphoma (MCL).
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, shares his advice for oncologists treating patients with chronic lymphocytic leukemia.
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia.
Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses a therapeutic option on the horizon for patients with mantle cell lymphoma (MCL) who are intolerant to ibrutinib (Imbruvica).
Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the ongoing efficacy but also challenges with ibrutinib (Imbruvica) as treatment for patients with chronic lymphocytic leukemia (CLL).
Kendra Sweet, MD, discusses the various factors that must be taken into account when prescribing first-line therapies to patients with CML, novel studies, and TKI discontinuation. 
Publication Bottom Border
Border Publication